Maximilian Mair

🧠 New EORTC survey shows PET imaging is widely available and used across European brain tumour centres. With data from 103 centres in 20 countries, the findings support PET-based endpoints in future trials. 🔗 Find out more: eortc.org/blog/2025/07/0… #EORTCbrain

Live from @NMMSymposium in Vienna: introduction of first RANO criteria for response assessment of brain metastases based on amino acid PET - with simultaneous publication in Nature Medicine. Learn more: nature.com/articles/s4159… #braincancer #PETimaging

Are you making an impact in #NeuroOncology research? The #EANOResearchAward honors outstanding contributions in the field. Apply now for a chance to be recognized at #EANO2025 in Prague! 📝 Nomination deadline: May 15 📩 Send your application to: awards@eano.eu #EANO #btsm

3/3 Together, these studies highlight the role of molecular profiling in brain tumors - from refining glioma classification to identifying radioligand therapy targets in meningioma. 🔬🧬 #btsm #neurooncology #neuropathology #nuclearmedicine @NMNSymposium

2/3 The 2nd study started from our efforts to molecularly reclassify a large Austrian 🇦🇹 retrospective #glioma cohort. We validated WHO 2021 & uncovered insights into rare subtypes & prognostic outliers, emphasizing the need for extended molecular workup. doi.org/n787

1/3 Excited to share two recent publications! 🧠💡 First, we explored radioligand target expression in high-grade #meningioma, finding #SSTR2a and #FAP variably expressed, w/ implications for patient selection and radioligand therapy design. @ProfNAlbert doi.org/n786

Excited to share our new paper on the validation and next-gen update of a DNA methylation-based recurrence predictor for meningioma - check it out now! @NeuroOnc @ICOMeningioma @ap_landry @gelarehzadeh @FarshadNassiri @justinzw @EANOassociation doi.org/10.1093/neuonc…

Happy to share our latest efforts of the RANO group published in @TheLancetOncol: thelancet.com/journals/lanon… and thelancet.com/journals/lanon… @UKKoeln @fz_juelich @SpyridonBakas @ph_lohmann #EANO

@antoniocafufa @BrainTumourOrg Wow, congrats! 🥳

It‘s a wrap! Safe travels home everyone after #EANO2024 meeting many colleagues (incl those of #YoungstersCommittee 👇) from all over the world. See you next year in Prague! #neurooncology #btsm @EANOassociation

Join us at the #EANO2024 #Youngsters Networking Event today! 🤝 Connect with fellow early-career scientists, share ideas, and expand your professional network. Don’t miss this opportunity! 🌟🚀🧠@EANOassociation #EarlyCareerResearchers #NeuroOncology #btsm

Looking forward to today’s #EANO2024 #Youngsters #Mentoring session on publishing successfully in #translational #research with @FilbinMariella & @DrSaraHam 📚🚀 Great tips from top researchers & editors - perfect for early-career scientists! 👨‍🔬👩‍⚕️ @EANOassociation

Official opening of #EANO2024 presenting the new logo on occasion of 30th anniversary. #HappyBirthdayEANO, and you all who are attending: do not miss the #EANOYoungsters track! eano.eu/eano-youngster… @EANOassociation #btsm #neurooncology

Dear fellow #EANOYoungsters - mark your calendar 🗓️ - sessions at #EANO2024 in Glasgow from youngsters for youngsters. @EANOassociation

Join us for the next #EANOJournalClub on Oct 1, 2024 (16:30-17:30 CEST)! Topic: CAR-T Cells in Glioma. Don't miss this deep dive into cutting-edge glioblastoma research. Learn more and register today bit.ly/3AHlOeI #btsm

Excited to present at the upcoming @EANOassociation #Youngsters JC on Oct 1, 2024! 🌐🚀🧠 Join us for an insightful discussion on #CARTcell therapy in #glioma with experts in the field. Check out the details and register today 👇 #glioblastoma #btsm #webinar #neurooncology

📄NEW cIMPACT GUIDELINE provides clear rec’s on harmonized molecular🧬grading, settles controversies after WHO CNS5, 🚨and: 1p loss for grading. Pleasure&privilege to jointly coordinate this with Arie Perry from @UCSF academic.oup.com/neuro-oncology…

🚀 Excited to share our @EORTC BTG Policy Review on the potential of #theranostics ☢️ in #NeuroOncology, exploring challenges & opportunities in developing targeted #radionuclide therapies & opening new avenues towards personalized care in #glioma, #meningioma, #brainmets & more.